Anti-Glomerular Basement Membrane (anti-GBM) Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Anti-Glomerular Basement Membrane (anti-GBM) Disease  Market Outlook

Thelansis’s “Anti-Glomerular Basement Membrane (anti-GBM) Disease  Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Anti-Glomerular Basement Membrane (anti-GBM) Disease  treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Anti-Glomerular Basement Membrane (anti-GBM) Disease  Overview

Anti-Glomerular Basement Membrane (anti-GBM) Disease is a rare form of small vessel vasculitis that affects the kidney and lung capillary beds. It is an archetypic autoimmune disease caused by the development of directly pathogenic autoantibodies targeting a well-characterized autoantigen expressed in the basement membranes of these organs. The body creates autoantibodies that recognize and attach to the basement membrane, which is part of the wall of capillary blood vessels in the kidneys and lungs. Once the autoantibodies bind to the basement membrane, this creates a signal to the body’s immune system to attack. However, the inciting events that induce the autoimmune response. In genetically susceptible individuals, environmental factors, such as the current infection, may trigger the disease. Most patients develop widespread glomerular crescent formation, presenting with signs and symptoms of rapidly progressing GN, and 40%–60% will have an alveolar hemorrhage at the same time. Treatment focuses on removing pathogenic autoantibody as quickly as possible, typically with plasma exchange, steroids, and cytotoxic therapy to stop ongoing autoantibody production and tissue inflammation. The body creates autoantibodies that recognize and attach to the basement membrane, which is part of the wall of capillary blood vessels in the kidneys and lungs. Once the autoantibodies bind to the basement membrane, this creates a signal to the body’s immune system to attack.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Anti-Glomerular Basement Membrane (anti-GBM) Disease  – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034